Compare JFR & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFR | FTRE |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2023 |
| Metric | JFR | FTRE |
|---|---|---|
| Price | $7.69 | $17.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 504.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $7.16 | $4.46 |
| 52 Week High | $8.55 | $18.67 |
| Indicator | JFR | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 60.09 |
| Support Level | $7.58 | $15.40 |
| Resistance Level | $7.71 | $18.13 |
| Average True Range (ATR) | 0.04 | 0.88 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 55.17 | 69.32 |
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.